CHEN Yuan,WANG Wei,TU Ming, et al. Effect of siRNA on proliferation of glioma cell line U87 by targeting fibroblast activation protein alpha[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(4): 241-244.
Abstract：Objective: To explore the effect of small interfering RNA (siRNA) -mediated fibroblast activation protein alpha knock-down on proliferation of glioma cell line U87. Methods: The experiment is divided into Blank, NC and siRNA. Negative control or siRNA were transfected into U87cells by Lipofectamine 2000. After transfection, protein level of target gene FAP-α, Bcl-2 and caspase-3 were detected by Western blot, mRNA level of PCNA and FAP-αwere detected by Real-time PCR. The proliferation ability of NC group and siRNA group of cells were analyzed by CCK8 assay. Results: ①Forty-eighth after transfection, mRNA and protein expressions of FAP-αin siRNA group were remarkably reduced as compared with those in NC and Blank group (P<0.05); Compared with NC group, the expression of caspase-3 was higher (P<0.05), while that of Bcl-2 was lower (P<0.01). The expression of PCNA mRNA was lower than NC group (P<0.01). ②The OD450 value of siRNA group was significantly lower than that in the NC group 24, 48, 72 and 96 h after transfection (P<0.05). Conclusion: siRNA-mediated fibroblast activation protein alpha knock-down can inhibit the proliferation of U87 glioma cells and promote apoptosis of glioma cells.
[1] Hirst TC, Vesterinen HM, Sena ES, et al. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?[J]. Br J Cancer, 2013,108(1): 64-71.
[2] Shah AH, Snelling B, Bregy A, et al. Discriminating radia-
tion necrosis from tumor progression in gliomas: a system-
atic review what is the best imaging modality?[J]. J
Neurooncol, 2013, 112(2): 141-152.
[3] Liu R, Li H, Liu L, et al. Fibroblast activation protein: A
potential therapeutic target in cancer[J]. Cancer Biol Ther,
2012, 13(3): 123-129.
[4] Collins PJ, McMahon G, O'Brien P, et al. Purification, iden-
tification and characterisation of seprase from bovine se-
rum[J]. Int J Biochem Cell Biol, 2004, 36(11): 2320-2333.
[5] Chen D, Kennedy A, Wang JY, et al. Activation of EDTA-
resistant gelatinases in malignant human tumors[J]. Cancer
Res, 2006, 66(20): 9977-9985.
[6] 武金波, 靳占峰. 成纤维细胞激活蛋白的表达与胃癌恶性生
物学行为的关系[J]. 黑龙江医学, 2008, 32(1): 21-23.
[7] Shi M, Yu DH, Chen Y, et al. Expression of fibroblast acti-
vation protein in human pancreatic adenocarcinoma and its
clinicopathological significance[J]. World J Gastroenterol,
2012, 18(8): 840-846.
[8] Liao Y, Ni Y, He R, et al. Clinical implications of fibroblast
activation protein-alpha in non-small cell lung cancer after
curative resection: a new predictor for prognosis[J]. J Can-
cer Res Clin Oncol, 2013, 139(9): 1523-1528.
[9] Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor
growth and increased microvessel density in a mouse model
of human breast cancer[J]. Cancer Res, 2004, 64(8): 2712-
2716.
[10] 温秋婷, 孙玉荣, 李春红, 等. 成纤维细胞激活蛋白对卵巢
癌细胞增殖、迁徙和侵袭的影响[J]. 中国癌症杂志, 2011,
21(6): 441-445.
[11] 朱琳, 张宁, 代海丽, 等. FAP对体外内皮细胞增殖及其小管
形成的影响[J]. 哈尔滨医科大学学报, 2012, 46(1): 10-13, 18.
[12] Stremenova J, Krepela E, Mares V, et al. Expression and
enzymatic activity of dipeptidyl peptidase-IV in human as-
trocytic tumours are associated with tumour grade[J]. Int J
Oncol, 2007, 31(4): 785-792.
[13] Mentlein R, Hattermann K, Hemion C, et al. Expression
and role of the cell surface protease seprase/fibroblast acti-
vation protein-alpha (FAP-alpha) in astroglial tumors[J].
Biol Chem, 2011, 392(3): 199-207.
[14] 翟广, 刘斌, 刘献志. 复发脑膜瘤血管内皮生长因子及增殖
细胞核抗原的表达[J]. 中华实验外科杂志, 2007, 24(11): 1308-
1309.
[15] 潘丹, 陈国荣, 金茹. PTEN基因和增殖细胞核抗原在喉鳞状
细胞癌中的表达及其意义[J]. 温州医学院学报, 2009, 39(3):
260-263.
[16] 金洲祥, 王向昱. 三氧化二砷联合5-氟尿嘧啶对小鼠肝癌
H22细胞株的抑制作用[J]. 温州医学院学报, 2013, 43(10):
655-659.
[17] Llambi F, Green DR. Apoptosis and oncogenesis: give and
take in the BCL-2 family[J]. Curr Opin Genet Dev, 2011,
21(1): 12-20.
[18] Way TD, Kao MC, Lin JK. Degradation of HER2/neu by
apigenin induces apoptosis through cytochrome c release
and caspase-3 activation in HER2/neu-overexpressing breast
cancer cells[J]. FEBS Lett, 2005, 579(1): 145-152.
